Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
Arakis Limited
company
About
Arakis Limited focuses on discovery and development of inflammatory diseases and oncology adjunctive therapy.
- 51 - 100
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- £16M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2000
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Arakis Limited is focuses on discovery and development of inflammatory diseases and oncology adjunctive therapy. The company's research capability specializes in the cytokine and receptor mediated mechanisms of disease. The company identifies, develops, and commercializes product opportunities based upon new clinical uses for known drugs or known drug templates, as well as termed performance enhanced medicines.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
£16M
Arakis Limited has raised a total of
£16M
in funding over 2 rounds. Their latest funding was raised on
Apr 26, 2002 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 26, 2002 | Series B | £16M | 1 |
Nomura International
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Arakis Limited is funded by 1 investors.
Nomura International
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Nomura International
|
Yes | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
